Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.500
-0.010 (-0.66%)
Dec 5, 2025, 4:00 PM EST - Market closed
Inhibikase Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Revenue | - | - | 0.26 | 0.12 | 3.1 | 0.7 | |
| Revenue Growth (YoY) | - | - | 111.03% | -96.02% | 343.92% | -37.79% | |
| Cost of Revenue | 30.63 | 17.21 | 13.62 | 12.03 | 11.36 | 0.89 | |
| Gross Profit | -30.63 | -17.21 | -13.36 | -11.91 | -8.26 | -0.2 | |
| Selling, General & Admin | 22.52 | 11.38 | 6.73 | 6.22 | 6.51 | 2.62 | |
| Operating Expenses | 22.52 | 11.38 | 6.73 | 6.22 | 6.51 | 2.62 | |
| Operating Income | -53.14 | -28.59 | -20.09 | -18.13 | -14.77 | -2.82 | |
| Interest Expense | - | - | - | - | -0.02 | -0.03 | |
| Interest & Investment Income | 3.47 | 1.07 | 1.06 | 0.07 | - | - | |
| Pretax Income | -47.66 | -27.52 | -19.03 | -18.05 | -14.79 | -2.85 | |
| Net Income | -47.66 | -27.52 | -19.03 | -18.05 | -14.79 | -2.85 | |
| Net Income to Common | -47.66 | -27.52 | -19.03 | -18.05 | -14.79 | -2.85 | |
| Shares Outstanding (Basic) | 85 | 24 | 6 | 4 | 3 | 1 | |
| Shares Outstanding (Diluted) | 85 | 24 | 6 | 4 | 3 | 1 | |
| Shares Change (YoY) | 1080.00% | 293.35% | 42.74% | 39.15% | 121.72% | 0.39% | |
| EPS (Basic) | -0.56 | -1.16 | -3.16 | -4.28 | -4.87 | -2.08 | |
| EPS (Diluted) | -0.56 | -1.16 | -3.16 | -4.28 | -4.87 | -2.08 | |
| Free Cash Flow | -25.63 | -19.15 | -18.1 | -17.59 | -14.3 | -1.13 | |
| Free Cash Flow Per Share | -0.30 | -0.81 | -3.00 | -4.17 | -4.71 | -0.82 | |
| Gross Margin | - | - | - | - | -266.35% | -27.97% | |
| Operating Margin | - | - | -7711.98% | -14686.17% | -476.23% | -403.52% | |
| Profit Margin | - | - | -7304.73% | -14625.86% | -476.88% | -407.73% | |
| Free Cash Flow Margin | - | - | -6947.87% | -14253.37% | -461.10% | -161.69% | |
| EBITDA | -53.08 | -28.56 | -19.91 | -18.12 | - | - | |
| D&A For EBITDA | 0.07 | 0.03 | 0.18 | 0.01 | - | - | |
| EBIT | -53.14 | -28.59 | -20.09 | -18.13 | -14.77 | -2.82 | |
| Revenue as Reported | - | - | 0.26 | 0.12 | 3.1 | 0.7 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.